Form 4: Enliven Therapeutics CEO Samuel Kintz Executes Stock Sales Under 10b5-1 Plan

Enliven Therapeutics CEO Samuel Kintz sold shares of common stock on October 8th and 9th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Samuel Kintz, the President and CEO of Enliven Therapeutics, executed multiple sales of common stock on October 8th and 9th, 2024.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• On October 8th, Kintz sold 13,167 shares at a weighted average price of $27.9546 and 100 shares at $28.51.
• On October 9th, Kintz sold 13,880 shares at a weighted average price of $28.0746 and 2,830 shares at $28.5264.
• Following these transactions, Kintz directly owns no shares, but indirectly owns 1,003,816 shares through The Kintz & Egan Trust Dated March 30, 2019, where he serves as trustee.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document simply reports insider trading activity under a pre-existing plan.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• While the sales are under a 10b5-1 plan, large insider sales can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any forward-looking statements about the company's future performance.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 plan provides a structured and legal framework for these transactions.

Stakeholder Impact

• The stock sales could potentially influence shareholder sentiment, although the existence of a 10b5-1 plan may mitigate concerns.

Key Dates